Neurocrine Biosciences, Inc. (NBIX) Stock Overview
Explore Neurocrine Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Neurocrine Biosciences, Inc. (NBIX)
Key Financials
Key Financials
Market Cap
17.7B
P/E Ratio
24.87
EPS (TTM)
$6.92
ROE
0.20%
NBIX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Neurocrine Biosciences, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of NBIX on the NASDAQ shows an RSI of 76.06, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $159.86 for the NASDAQ listing.
Key metrics behind Neurocrine Biosciences, Inc.'s NASDAQ-traded stock include a P/E ratio of 24.87 and a market capitalization of 17.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of NBIX on the NASDAQ.